

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 1 3 2002

Serial No.: 09/936,565

Group Art Unit: 1646

.. 1 0 2002

Filed: February 4, 2002

Examiner: TBA

TECH CENTER 1600/2900

For: SURFACE LOCALIZED COULIGGERASPAREN CARCINOMA CELLS

John J. SAUK

## INFORMATION DISCLUSURE GEATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

COPY OF PAPERS ORIGINALLY FILED

Sir:

The subject disclosures A4 and A5 were cited in the International Search Report dated August 15, 2000. The PCT International Division of the U.S. Patent and Trademark Office has confirmed receipt of the Acceptance mailed March 27, 2002. Therefore, copies of those references are not supplied.

Applicants respectfully request the Examiner to confirm review of such documents by initialing and returning the attached PTO-1449.

### **FEES**

No fee is required for this Information Disclosure Statement because:
This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
☐ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
A fee is required for this Information Disclosure Statement

Austington 100, 2023 from Same Signature.

notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).

This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.

#### CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

### **DEPOSIT ACCOUNT**

If a fee is due, attached is a check in the amount of \$\sum\_\text{.}\$ However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Nancy J. Axelrod, Reg. No. 44,014
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201

Telephone (703) 243-6333 Facsimile: (703) 243-6410

FILED: May 3, 2002

Approved to Jse through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons ar	e legured to respond to a collection	n of information unless it contains a valid OMB control
Substitute for form 1449A/PTO	<b>5</b> 7%	Complete if Known
	Application Number	09/936,565
NFORMATION DISCLOSURE	Filing Date	February 4, 2002

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

/	Complete ii Known	1
Application Number	09/936,565	
Filing Date	February 4, 2002	
First Named Inventor	John J. SAUK	
Group Art Unit	1646	
Examiner Name	TBA	
Attorney Docket Number	UNIMD-4	

			U.S. PATENT DOCU	MENTS			
-		U.S. Patent Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Initials	Cite No	Number Kind Code <sup>2</sup> (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		
	A1	5,932,478	Multhoff	8/3/99			
	A2	5,962,424	Hallahan et at	10/5/99			
			COPY OF PA	PERS	RECEIVED		
	<del> </del>		ORIGINALLY				
					MAY 1 3 2002		
					TECH CENTER 1600/29		
	ļ				TEOTIOE TELL 1000/E0		

	FOREIGN PATENT DOCUMENTS								
Examiner	Foreign Patent Document		Name of Patentee	Date of Publication of	Pages, Columns, Lines,	T			
Initials*	Cite No	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>	
	: •	t	· •	<del>-                                    </del>					
	•	•	<b>.</b>	- :		•			
		1							

4			
I	Examiner Signature	Date Considered	
м			

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

\*\*Unique citation designation number \*\*See attached Kinds of U.S. Patent Documents \*\*Enter Office that issued the document, by the two-letter code :WIPO Standard ST 31 \*\*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document \*\*Skind of document by the appropriate symbols as indicated on the document order WIPO Standard ST 16 if possible \*\*Applicant is to provide the kilmark here if English, anguage Translation is attached

								_
Please type	а	olus	SION	(+)	inside	this	box	

/		6	- 1	
	MAY 0	9 2002	(CR)	•
			. /	Ann

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no peace, are required bespond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

WAY!	
	Complete if Known
Application Number	09/936,565
Filing Date	February 5, 2002
First Named Inventor	John J. SAUK
Group Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	UNIMD-4

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	<b>A</b> 3	Larocca et al., "Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage," The FASEB Journal, Vol. 13, April 1999, pp. 727-734	
	Α4	Database Medline on Dialog, US National Llibrary of Medicine, (Bethesda, MD, USA), No. 1999436824 RAZZAQUE et al., "The possible role of colligin/hsp 47, a collagen binding protein in the pathogenesis of human and experimental fibrotic diseases," Histology and Histopathology. October 1999, Vol. 14, No. 4, pp. 199-1212	
	<b>A</b> 5	Database Medline on Dialog, US National Library of Medicine, (Bethesda, MD, USA), No. 1999241927 NORRIS et al. "Cell Surface Colligin/Hsp47 associates with tetraspanin protein CD9 in epidermoid carcinoma cell lines,"  Journal of cellular Biochemistry, May 1999, Vol. 73, No. 2, pp. 248-258	
		RECEN	ΙΕΙ
		ORIGINALLY FILED MAY 1 3	2002
		TECH CENTER 1	600,29

	 _	
Examiner	Date	
Signature	Considered	

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEF 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applica it.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. U.S. Patent and Trademark. Office. Washington. DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington. DC 20231.

Unique citation designation number 2 Applicant is to place a check mark here if English language Translation is attached